Barclays’s Atossa Therapeutics ATOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-1,251
| Closed | -$15.6K | – | 5478 |
|
|
2025
Q2 | $15.6K | Sell |
1,251
-7,321
| -85% | -$87.5K | ﹤0.01% | 4867 |
|
|
2025
Q1 | $86.5K | Sell |
8,572
-4,225
| -33% | -$51.3K | ﹤0.01% | 4458 |
|
|
2024
Q4 | $181K | Buy |
12,797
+1,616
| +14% | +$31.6K | ﹤0.01% | 4360 |
|
|
2024
Q3 | $255K | Buy |
11,181
+8,245
| +281% | +$166K | ﹤0.01% | 4174 |
|
|
2024
Q2 | $52.4K | Buy |
+2,936
| New | +$65K | ﹤0.01% | 4193 |
|
|
2022
Q3 | – | Sell |
-7
| Closed | – | – | 4778 |
|
|
2022
Q2 | $0 | Sell |
7
-1,266
| -99% | -$19.9K | ﹤0.01% | 5013 |
|
|
2022
Q1 | $24K | Sell |
1,273
-8,194
| -87% | -$166K | ﹤0.01% | 4388 |
|
|
2021
Q4 | $227K | Buy |
9,467
+6,280
| +197% | +$230K | ﹤0.01% | 3519 |
|
|
2021
Q3 | $156K | Buy |
3,187
+1,649
| +107% | +$95.9K | ﹤0.01% | 3733 |
|
|
2021
Q2 | $145K | Sell |
1,538
-2,842
| -65% | -$150K | ﹤0.01% | 3688 |
|
|
2021
Q1 | $139K | Buy |
4,380
+3,592
| +456% | +$131K | ﹤0.01% | 3866 |
|
|
2020
Q4 | $11K | Hold |
788
| – | – | ﹤0.01% | 4741 |
|
|
2020
Q3 | $29K | Buy |
+788
| New | +$37.8K | ﹤0.01% | 4810 |
|
|
2019
Q4 | – | Sell |
-3
| Closed | – | – | 6332 |
|
|
2019
Q3 | $0 | Sell |
3
-367
| -99% | -$11.6K | ﹤0.01% | 6696 |
|
|
2019
Q2 | $14K | Sell |
370
-112
| -23% | -$4.49K | ﹤0.01% | 6483 |
|
|
2019
Q1 | $25K | Sell |
482
-1,677
| -78% | -$48.9K | ﹤0.01% | 6259 |
|
|
2018
Q4 | $33K | Buy |
+2,159
| New | +$42.7K | ﹤0.01% | 5680 |
|
|
2018
Q2 | – | Sell |
-895
| Closed | -$72K | – | 6954 |
|
|
2018
Q1 | $72K | Buy |
+895
| New | +$83.4K | ﹤0.01% | 5617 |
|
|
2017
Q2 | – | Sell |
-11
| Closed | -$2K | – | 6625 |
|
|
2017
Q1 | $2K | Buy |
+11
| New | +$2.81K | ﹤0.01% | 6447 |
|
|
2013
Q3 | – | Sell |
-1
| Closed | -$14K | – | 7391 |
|
|
2013
Q2 | $14K | Buy |
+1
| New | +$16.9K | ﹤0.01% | 6982 |
|
Other funds holding ATOS
GCP
